

## [Adalimumab](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics 8.1. Immunomodulators for non-malignant disease](#)

ATC codes: [L04AB04](#)

EMLc

Indication

Crohn disease site ICD11 code: [DD70.Z](#)

INN

Adalimumab

Medicine type

Biological agent

List type

Complementary

Additional notes

EML: certolizumab pegol, etanercept, golimumab and infliximab are alternatives, including quality-assured biosimilars.

EMLc: etanercept and infliximab are alternatives, including quality-assured biosimilars.

Formulations

**Parenteral > General injections > SC:** 40 mg per 0.8 mL ; 40 mg per 0.4 mL ; 10 mg per 0.2 mL (EMLc) ; 20 mg per 0.4 mL (EMLc)

EML status history

First added in 2019 ([TRS 1021](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

[certolizumab pegol](#) (ATC codes: [L04AB05](#))

[etanercept](#) (ATC codes: [L04AB01](#))

[golimumab](#) (ATC codes: [L04AB06](#))

[infliximab](#) (ATC codes: [L04AB02](#))

Patent information

Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit [www.MedsPal.org](http://www.MedsPal.org)

Read more [about patents](#).

Tags

Biological

Wikipedia

[Adalimumab](#)

DrugBank

[Adalimumab](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of adalimumab (injection 10 mg/0.2 mL and 20 mg/0.4 mL) to the EMLc.